Evidence map›Paper›PMID 41867589›Full record

ArticleACS omega2026

Physicochemical Stability of Insulin and Analogues in Saline Infusion: Screening for Amyloid and Amorphous High-Molecular-Weight Material.

João Gabriel da Cruz E Silva, Fernando de Sá Ribeiro, Luís Maurício T R Lima

Abstract read
In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

João Gabriel da Cruz E SilvaLaboratório de Biotecnologia Farmacêutica - pbiotech, Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ 21941-902, Brazil.ORCID https://orcid.org/0009-0003-6079-2062
Fernando de Sá RibeiroLaboratório de Biotecnologia Farmacêutica - pbiotech, Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ 21941-902, Brazil.ORCID https://orcid.org/0000-0002-8521-6745
Luís Maurício T R LimaLaboratório de Biotecnologia Farmacêutica - pbiotech, Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ 21941-902, Brazil.ORCID https://orcid.org/0000-0001-6020-0504

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Insulin is known to form subvisible particles and amyloid material, which can lead to iatrogenic amyloidosis and reduced potency necessary for glycemic control. In the intensive care unit, insulin is commonly diluted in saline (1-unit/mL) for intravenous infusion. While reports of insulin aggregation in such dilutions exist, it remains unclear whether these conditions favor the formation of amyloid or subvisible particles. Here, we report standardized assays for detecting amorphous and amyloid insulin aggregation and applied them to investigate these particles in insulin infusion setups. Amorphous insulin was produced by heating insulin (100 U/mL) in plastic tubes, while amyloid insulin formed within 3 days by incubating in saline or sodium phosphate buffer, pH 7.0. Electron microscopy confirmed the amyloid nature of these aggregates, and dynamic light scattering detected subvisible particles as low as 0.05 U/mL. Insulin incubated at 1-unit/mL in saline showed no detectable amyloid material or subvisible particles up to 48 h at room temperature. These results suggest that insulin diluted to 1-unit/mL in saline does not form detectable amyloid or subvisible particles under the tested conditions and that these analytical approaches may be helpful for other biopharmaceuticals.

Identifiers

PMID41867589
PMCPMC13000647

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.